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Abstract
Background: Tong Luo Hua Shi (TLHS) is a new formulation of the traditional Tibetan medicine Wu-wei-gan-lu that
has been used for the treatment of rheumatoid arthritis (RA) for hundreds of years in China. This study aimed to
evaluate the efficacy and safety of TLHS in patients with RA.
Methods: This was a randomized, double-blind, placebo-controlled, dose-finding study performed in patients with
active RA from five medical centers. Patients received three doses (4.8, 3.6, or 2.4 g/day po) of TLHS or placebo (tid
po) for 8 weeks. Blood sampling, physical examination, and assessment of the American College of Rheumatology
(ACR) 20 % improvement (ACR20) criteria were performed before and every 2 weeks after starting treatment. The
primary endpoint was the ACR20. The secondary endpoints included safety.
Results: A total of 240 participants were screened and 236 patients were randomized (n = 59/group); 20 dropped
out. After 8 weeks, ACR20 improvements in the TLHS 4.8 g and 3.6 g groups were significantly higher than in the
placebo group (P < 0.01 and P < 0.05, respectively). ACR50 improvement in the TLHS 4.8 g group was significantly
higher compared with the placebo group (P < 0.01). Symptoms of RA were significantly relieved in the TLHS groups.
In the TLHS groups, insomnia (n = 1), gastroenteric reactions (n = 2), arrhythmia (n = 1), and minor hepatic lesion
(n = 1) were reported; in the placebo group, hepatic dysfunction (n = 1) was reported (P = 0.878).
Conclusions: TLHS improved the symptoms of patients with RA according to the ACR20. Moreover, TLHS was safe.
Trial registration: Chinese Clinical Trial Registry: ChiCTR-TRC-12003871. Registered on 1 January 2012.
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Background
Rheumatoid arthritis (RA) is a chronic inflammatory
disease characterized by persistent synovitis and progres-
sive destruction of cartilage and bone with the presence
of rheumatoid factors. RA is also associated with sys-
temic inflammatory manifestations in addition to local
inflammation of multiple joints [1–3]. The prevalence of
RA is 0.35 % in women and 0.13 % in men [4]. Risk fac-
tors include smoking, genetic factors, elevated rheuma-
toid factor levels, elevated soluble tumor necrosis factor
receptor II levels, coffee consumption, absence of hor-
monal replacement therapy, and posttraumatic stress
disorder [5–9]. Treatment of RA involves the control of
inflammation using anti-inflammatory drugs [1, 2].
Tong Luo Hua Shi (TLHS) capsules are a new formula-
tion of the traditional Wu-wei-gan-lu decoction, which is
one of the basic medicines in traditional Tibetan medicine
for the treatments of different diseases, especially RA, and
has been used for hundreds of years in China [10–12].
TLHS is made from herbs including Salvia miltior-
rhiza, Ephedra intermedia, Sabina przewalskii, Myri-
caria paniculata, Artemisia sieversiana, Astragalus
membranaceus, and Rhododendron anthopogonoides
[10–12]. Previous studies of the Wu-wei-gan-lu decoc-
tion revealed its efficacy for the treatment of acute
gouty arthritis [13] and RA [14, 15].
Therefore, the aim of the present study was to evaluate
the efficacy and safety of TLHS in patients with RA.
Methods
Study design
This was a multicenter, randomized, double-blind,
placebo-controlled, dose-finding trial. It was reported
according to the recommendation of the Consolidated
Standards of Reporting Trials (CONSORT) [16]. The trial
was approved by the State Food and Drug Administration
of China (No. 2006 L03370) and the ethical committee of
The First Teaching Hospital of Tianjin University of Trad-
itional Chinese Medicine (No. TYLL2009015). Written
informed consent was obtained from each participant be-
fore enrollment. The trial was registered with the Chinese
Clinical Trial Registry (registration number: ChiCTR-
TRC-12003871; date of registration: 1 January 2012).
The manuscript was in accordance with the populated
CONSORT checklist (see Additional file 1) and flow
diagram (see Additional file 2).
This study took place in five centers: the First Teaching
Hospital of Tianjin University of Traditional Chinese
Medicine, the Affiliated Hospital of Liaoning University of
Traditional Chinese Medicine, the Traditional Chinese
Medicine Hospital of Xinjiang Uygur Autonomous Re-
gion, the Hubei Hospital of Traditional Chinese Medicine,
and the Tibetan Medicine Hospital of Qinghai Province.
Participants
Participants (n = 236) were recruited between May 2009
and June 2011. Participants had to have been diagnosed
with RA according to the American College of Rheuma-
tology (ACR) 1991 revised criteria [17]. All participants
had to have an ACR functional class of I, II, or III, and
be in radiographic stage I, II, or III.
Exclusion criteria were: (1) pregnant or lactating
women, and women of child-bearing age who were not
using an effective method of contraception; (2) severe
disability; (3) history of serious allergic reactions; (4) any
other concurrent rheumatic disease such as systemic
lupus erythematosus, Sjogren’s syndrome, or severe
osteoarthritis; (5) significant cardiac, hematologic, re-
spiratory, neurological, endocrine, renal, hepatic, gastro-
intestinal, or psychotic disease; (6) active recurrent
infection; (7) alcoholism or drug dependency; or (8) psy-
chological disorder.
Nonsteroidal anti-inflammatory drugs (NSAIDs) were
discontinued at least 30 days before participation. Partic-
ipants receiving a stable dosing regimen of the same glu-
cocorticoids, e.g., prednisolone (10 mg daily maximum),
or disease-modifying antirheumatic drugs (DMARDs)
prior to entering the study were allowed.
If severe pain or complications occurred in a patient,
making it impossible to participate in the study, as con-
firmed by the investigator, the patient was removed from
the study. Poor compliance to treatment or study proto-
col led to removal from the study. Otherwise, patients
could drop out of the study if they wished to; the
reasons for dropping out were recorded. If a patient
dropped out because of poor treatment effect, this pa-
tient was analyzed as achieving no treatment efficacy.
Study medication and administration
The TLHS and placebo capsules were provided by
Lanzhou Heshengtang Pharmaceutical Co., Ltd. (Lanzhou,
China). Placebos were supplied in the form of capsules
matched for weight, shape, and color.
The patients were randomized to receive 4.8, 3.6, or
2.4 g/day (three pills/day) of TLHS po or placebo po. All
patients consumed four capsules each time and the dose
was adjusted using a combination of TLHS and placebo
capsules. An independent statistician prepared sequen-
tial sealed envelopes based on a random number table
generated using SAS 9.2 (SAS Institute, Cary, NC, USA).
Randomization was implemented without blocks. The
envelopes and the allocation sequence were managed by
a statistician. When a patient was recruited, the treat-
ing physician phoned the independent statistician,
who then opened the next envelope and phoned the
pharmacist to state the allocation. Capsules were pre-
pared by the pharmacist. Patients and physicians were
blinded to grouping.
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Table 1 Baseline characteristics of the participants
Characteristic TLHS 4.8 g TLHS 3.6 g TLHS 2.4 g Placebo
Age, years, mean ± SD 47.54 ± 11.14 50.76 ± 9.69 50.59 ± 10.61 50.12 ± 10.45
Gender, n, M : F 12:47 11:48 8:51 7:52
Height, cm, mean ± SD 162.88 ± 6.49 162.08 ± 6.16 161.78 ± 5.40 162.37 ± 5.60
Weight, kg, mean ± SD 61.83 ± 9.87 61.04 ± 9.65 60.14 ± 9.04 61.88 ± 9.29
Marital status, married : other 53:6 56:3 55:4 56:3
Duration of disease, months 3.00–180.00 2.00–216.00 5.00–183.00 2.00–276.00
Medication, use : no use 20:39 28:31 32:27 28:31
Radiographic stage, I : II : III 30:25:4 23:32:4 27:22:10* 33:21:5
Joint functional stage, I : II : III 13:46:0 9:47:3 9:42:8 15:40:4
Pain (VAS), cm, mean ± SD 5.68 ± 1.12 5.68 ± 1.27 5.48 ± 1.19 5.52 ± 1.13
Tender joint counts, n, mean ± SD 9.12 ± 5.07 8.47 ± 5.06 7.36 ± 3.87 9.24 ± 5.33
Swollen joint counts, n, mean ± SD 6.27 ± 3.47 5.83 ± 3.34 5.20 ± 2.54 6.19 ± 3.57
Morning stiffness, min, mean ± SD 82.03 ± 37.73 81.36 ± 37.61 83.31 ± 50.88 90.25 ± 71.24
Grip strength, mmHg, mean ± SD 36.11 ± 25.84 32.53 ± 22.57 35.07 ± 24.00 34.87 ± 24.97
Physician’s assessments, score, mean ± SD 5.32 ± 1.12 5.34 ± 1.33 5.07 ± 1.11 5.30 ± 1.17
HAQ, score, mean ± SD 16.68 ± 11.87 18.10 ± 12.78 15.39 ± 11.09 17.07 ± 12.85
RF, U/ml, mean ± SD 163.69 ± 258.04 74.72 ± 110.88 99.19 ± 149.96 79.04 ± 131.09
CRP, mg/dl, mean ± SD 7.38 ± 15.13 11.11 ± 30.01 6.83 ± 12.42 7.49 ± 16.67
ESR, mm/h, mean ± SD 22.39 ± 19.73 27.21 ± 25.14 27.93 ± 25.00 26.39 ± 23.04
*P < 0.05 versus the placebo group
VAS visual analog scale, HAQ Health Assessment Questionnaire, RF rheumatoid factor, CRP C-reactive protein, ESR erythrocyte sedimentation rate
Fig. 1 Flowchart of the participants
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According to the pain status and for all patients, in-
cluding the patients in the placebo group, 25 mg of
diclofenac sodium enteric-coated tablets (Voltaren,
Beijing Novartis Pharmaceutical Co., Ltd., Beijing,
China) bid or tid, and/or 20 mg of leflunomide (Fujian
Huitian Biological Pharmaceutical Co., Ltd., Fuzhou
City, China) were allowed, if necessary, after the sec-
ond week of treatment, according to the treating phy-
sician’s judgment. The treating physician was blind to
the study treatment.
Endpoints
The primary efficacy endpoint was the improvement in
ACR20 [18, 19]. Secondary endpoints were rheumatoid
factor (RF) levels, C-reactive protein (CRP) levels,
erythrocyte sedimentation rate (ESR), ACR50, ACR70,
and safety.
Efficacy and safety
Safety was monitored until the last administration of
TLHS or placebo. Frequency and severity of adverse ef-
fects and adverse drug reactions were observed at each
visit. Clinical and laboratory tests such as tender and
swollen joint counts based on Disease Activity Score 28
(DAS28) [20], morning stiffness, average grip strength of
two hands, 100-mm visual analog scale (VAS), and Health
Assessment Questionnaire (HAQ)-disability index,
were assessed by the investigators at screening, base-
line, and at weeks 2, 4, and 8. Standard hematological
and biochemical tests and urine analysis were also
performed at each study site.
Statistical analysis
No data about TLHS was available in the literature on
which to base the power analysis. However, based on data
about Wu-wei-gan-lu, we estimated that the effective rate
should be about 50 % in the control group and about 75–
80 % in the 4.8 g group. By setting the power at 80 %, α at
0.05, and the same sample size in each group, the min-
imal sample size for each group was between 39 and
59. By considering the drop-out rate, limitation of
funds, and probable errors in estimating the effective
rate, we decided to include 60 patients in each group.
The efficacy analysis was performed using the intent-
to-treat principle, which includes all randomized partici-
pants who underwent at least one post-treatment evalu-
ation. The last observation carried forward method was
used to substitute for missing data. The safety analysis
was performed on all participants who received at least
one dose of study medication.
Continuous data are presented as mean ± standard
deviation (SD) and were analyzed using one-way ana-
lysis of variance (ANOVA) and Tukey’s post hoc test.
Categorical data are presented as frequencies and were
analyzed using the chi-square test or Fisher’s exact test,
as appropriate. Statistical testing, unless otherwise
stated, was two-sided and used a 5 % significance
threshold. Data were analyzed with SAS 9.2 (SAS Insti-
tute, Cary, NC, USA).
Results
Characteristics of the participants
A total of 240 participants from five centers were screened
between May 2009 and June 2011 and provided a written
informed consent (Fig. 1); 216, 236, and 236 participants
were included in the per-protocol set (PPS), the full
analysis set (FAS), and the safety set (SS), respectively.
Four patients could not be randomized because four sets
of drugs/placebo (one in each group) had reached the ex-
piration date before recruiting a subject. The decision was
then taken to stop the study because the scientific
Table 2 Adverse events and adverse drug reactions
Event/reaction TLHS 4.8 g TLHS 3.6 g TLHS 2.4 g Placebo
Adverse events, n (%) 3 (5.1) 2 (3.4) 3 (5.1) 3 (5.1)
Adverse drug reactions,
n (%)
2 (3.4) 1 (1.7) 2 (3.4) 1 (1.7)
Table 3 Effective rate according to the ACR20, ACR50, and ACR70
FAS, n (%) PPS, n (%)
ACR70 ACR50 ACR20 ACR70 ACR50 ACR20
TLHS 4.8 g 6 (10.2) 24 (40.7)**,**** 45 (76.3)*,*** 6 (11.3) 23 (43.4)**,**** 44 (83.0)**,****
TLHS 3.6 g 2 (3.4) 14 (23.7) 43 (72.9)* 2 (3.7) 14 (25.9) 42 (77.8)*,***
TLHS 2.4 g 1 (1.7) 9 (15.3) 33 (55.9) 1 (1.8) 9 (15.8) 33 (57.9)
Placebo 3 (5.1) 8 (13.6) 32 (54.2) 3 (5.8) 8 (15.4) 29 (55.8)
ACR American College of Rheumatology response criteria, FAS full analysis set, PPS per protocol set
*P < 0.05 versus the placebo group
**P < 0.01 versus the placebo group
***P < 0.05 versus the 2.4 g group
****P < 0.01 versus the 2.4 g group
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Table 4 Condition of the participants at end of the trial
Indications FAS PPS
TLHS 4.8 g TLHS 3.6 g TLHS 2.4 g Placebo TLHS 4.8 g TLHS 3.6 g TLHS 2.4 g Placebo
Pain (VAS), cm, mean ± SD 2.62 ± 1.37** 3.31 ± 1.30** 3.64 ± 1.29 3.99 ± 1.42 2.48 ± 1.30** 3.24 ± 1.32* 3.62 ± 1.30 3.89 ± 1.45
Pain changes, cm, mean ± SD −3.06 ± 1.95** −2.37 ± 1.31** −1.85 ± 1.51 −1.53 ± 1.70 −3.31 ± 1.87** −2.44 ± 1.25* −1.88 ± 1.51 −1.63 ± 1.74
Tender joint counts, n, mean ± SD 3.88 ± 3.73** 4.80 ± 3.24 4.24 ± 2.54* 5.63 ± 4.10 3.96 ± 3.89 4.80 ± 3.38 4.19 ± 2.53 5.67 ± 4.32
Tender joint changes, n, mean ± SD −5.24 ± 3.54** −3.68 ± 3.19 −3.12 ± 2.88 −3.61 ± 3.51 −5.66 ± 3.46 −3.81 ± 3.24 −3.21 ± 2.88 −3.96 ± 3.54
Swollen joint counts, n, mean ± SD 2.24 ± 2.09** 2.68 ± 1.82 3.03 ± 1.88 3.41 ± 2.49 2.30 ± 2.13 2.56 ± 1.77 3.02 ± 1.90 3.31 ± 2.47
Swollen joint changes, n, mean ± SD −4.03 ± 3.58* −3.15 ± 2.48 −2.17 ± 2.43 −2.78 ± 2.96 −4.38 ± 3.61* −3.31 ± 2.43 −2.30 ± 2.37 −3.04 ± 3.01
Morning stiffness, min, mean ± SD 36.53 ± 24.69** 46.10 ± 26.57 50.14 ± 36.08 54.93 ± 41.78 35.00 ± 23.27** 45.56 ± 27.29 50.14 ± 36.67 55.21 ± 44.38
Morning stiffness changes, min, mean ± SD −45.51 ± 34.71 −35.25 ± 21.40 −33.17 ± 28.42 −35.32 ± 42.23 −50.09 ± 33.56 −38.15 ± 19.96 −33.81 ± 28.70 −39.12 ± 43.33
Grip strength, mmHg, mean ± SD 47.68 ± 28.59 38.80 ± 24.49 40.58 ± 26.27 38.84 ± 25.12 47.14 ± 29.13 36.00 ± 23.63 39.63 ± 26.22 36.99 ± 25.07
Grip strength changes, mmHg, mean ± SD 11.57 ± 21.19** 6.27 ± 7.07 5.51 ± 10.01 3.97 ± 8.53 12.32 ± 22.21** 6.76 ± 6.98 5.70 ± 10.13 3.93 ± 8.75
Physician’s assessments, score, mean ± SD 2.65 ± 1.40** 3.32 ± 1.37 3.62 ± 1.34 3.79 ± 1.42 2.52 ± 1.34** 3.24 ± 1.37 3.62 ± 1.36 3.68 ± 1.45
Physician’s assessments changes, score, mean ± SD −2.67 ± 1.91** −2.02 ± 1.36 −1.45 ± 1.48 −1.51 ± 1.65 −2.92 ± 1.84** −2.07 ± 1.30 −1.46 ± 1.49 −1.60 ± 1.71
HAQ, score, mean ± SD 10.31 ± 9.91 12.69 ± 11.05 11.36 ± 9.64 12.92 ± 11.35 11.19 ± 10.06 12.89 ± 11.25 11.65 ± 9.67 13.60 ± 11.64
HAQ changes, score, mean ± SD −6.37 ± 8.60 −5.41 ± 6.98 −4.03 ± 5.60 −4.15 ± 7.90 −6.89 ± 8.89 −5.83 ± 7.13 −4.18 ± 5.64 −4.31 ± 8.13
RF, U/ml, mean ± SD 122.61 ± 194.75 60.55 ± 99.04 90.35 ± 160.68 64.88 ± 102.79 129.88 ± 203.21 63.42 ± 104.21 93.28 ± 165.28 67.93 ± 109.24
CRP, mg/dl, median ± IQR 12.63 ± 44.50 5.68 ± 10.62 5.48 ± 8.48 6.81 ± 15.15 14.05 ± 47.27 5.75 ± 11.03 5.78 ± 8.70 7.25 ± 16.20
ESR, mm/h, mean ± SD 21.24 ± 21.91 21.32 ± 24.15 22.95 ± 20.24 23.25 ± 19.66 20.69 ± 21.89 21.39 ± 25.25 23.75 ± 20.42 24.26 ± 20.56
Joint functional stage, I : II : III 22:37:0 14:44:1 16:40:3 20:37:2 21:32:0 14:39:1 16:38:3 19:32:1
Voltaren use : no use 3:56** 10:47** 20:38** 23:33 3:50** 9:45** 20:37 21:31
Frequency of Voltaren use, mean ± SD 7.40 ± 8.08** 17.80 ± 13.02** 22.03 ± 17.11** 39.32 ± 20.13 7.40 ± 8.08** 17.63 ± 13.35** 22.03 ± 17.11** 39.29 ± 20.34
Leflunomide use : no use 14:45 22:35 22:36 24:32 41:39 20:34 22:35 22:30
FAS full analysis set, PPS per protocol set, VAS visual analog scale, HAQ Health Assessment Questionnaire, RF rheumatoid factor, CRP C-reactive protein, ESR erythrocyte sedimentation rate
*P < 0.05 and **P < 0.01 versus the placebo group. There were 226 patients in these four groups. Ten patients dropped out before the first follow-up at 2 weeks. The other dropouts were included in this table using









committee wanted to use the same batch of drugs for all
patients. Twenty participants dropped out (Fig. 1).
Except for the radiographic stage (P = 0.031), there was
no clinically significant difference between the groups at
baseline (all P > 0.10) (Table 1).
Safety
Treatment tolerance was good. In the TLHS 4.8 g group,
one case of insomnia and one case of gastroenteric reac-
tion were reported. In the 3.6 g group, there was one
case of arrhythmia. In the 2.4 g group, one case of upset
stomach and one case of minor hepatic lesion were re-
ported. A case of hepatic dysfunction was reported in
the placebo group. There was no significant difference in
the incidences of adverse events (P = 0.963) or adverse
drug reactions (P = 0.878) between the groups (Table 2).
No serious adverse event occurred in the trial.
Effective rate of the ACR improvement
After 8 weeks, the improvement rates of the ACR20 in
the TLHS 4.8 g and 3.6 g groups were significantly
higher than in the placebo group (P = 0.012 and P =
0.035 in FAS, respectively; P = 0.002 and P = 0.016 in
PPS, respectively). The improvement rate of the ACR20
in the 4.8 g group was higher than in the TLHS 2.4 g
group (P = 0.020 in FAS; P = 0.004 in PPS). The improve-
ment rate of the ACR50 in the TLHS 4.8 g group was sig-
nificantly higher compared with the placebo group (P =
0.001 in FAS; P = 0.002 in PPS) and the TLHS 2.4 g group
(P = 0.002 in FAS; P = 0.001 in PPS) (Table 3).
Secondary outcomes
The symptoms of the participants after treatments were
significantly relieved. There were significant differences
in the symptoms of RA between the TLHS groups and
the placebo group after 8 weeks of treatments (Table 4).
Discussion
TLHS is a new formulation of the traditional Tibetan
medicine Wu-wei-gan-lu decoction that has been used
for the treatment of RA for hundreds of years in China.
This study aimed to evaluate the efficacy and safety of
TLHS in patients with RA. Results showed that after
8 weeks, ACR20 improvement in the TLHS 4.8 g and
3.6 g groups was significantly higher than in the placebo
group. ACR50 improvement in the TLHS 4.8 g group
was significantly higher compared with the placebo
group. There was no difference in adverse events be-
tween the groups. TLHS improved the symptoms of
patients with RA according to the ACR20. Moreover,
TLHS was safe.
The quality of TLHS in China is controlled by HPLC
analysis [21, 22]. In previous pharmacodynamics studies,
TLHS revealed obvious inhibitory effects on swollen feet
induced by albumen, formaldehyde, or adjuvant injec-
tions, and on edema of the ears of mice induced by xylene
[23, 24]. In addition, studies have shown that TLHS re-
duced the writhing responses to acetic acid injection and
tail flick against thermal stimulation [10, 25–29]. It can also
increase the coagulation time and regulate the phagocytic
immunity of macrophages in mice. Toxicology studies sug-
gested that after giving high, moderate, or low doses of
TLHS for 6 months, the hematologic, biochemical, and
histopathological indexes were normal [10, 25–29]. Fur-
thermore, experimental data showed that the maximum
tolerable dose of TLHS was as high as 75.6 g/kg, which is
equivalent to 300 times the clinical dose for adults. Previous
clinical trials showed that the basic formula of TLHS, Wu-
wei-gan-lu decoction, has immunoregulatory and antiar-
thritic effects for treating RA [14, 15].
The present study suggests that TLHS may be used to
treat the symptoms of RA and to improve the quality of
life, and that it is safe. On one hand, it demonstrated a
good mid-term safety profile and good treatment com-
pliance, in spite of some mild and transient adverse
events or reactions including insomnia, gastroenteric re-
actions, and arrhythmias. On the other hand, the symp-
toms such as pain, tenderness, swelling, and morning
stiffness were improved by TLHS. The patients’ grip
strength and their conditions assessed by the physician
could also be improved. Finally, fewer painkillers were
needed by the patients. Nevertheless, it must be stressed
that these results were obtained in a Chinese population
and that traditional Chinese medicine is seldom used in
Western countries.
The present study is not without limitations. Even if it
was a multicenter trial, the sample size was relatively
small. Second, only a limited panel of inflammatory
markers was assessed. Further study is necessary to de-
termine the comprehensive mechanisms of TLHS on
inflammation. Larger studies are necessary to adequately
demonstrate the effects of TLHS on RA. Other chronic
inflammatory conditions might also benefit from TLHS.
Conclusions
The results of the present study showed that TLHS is
safe and effective in improving the primary effective
values and reducing the secondary symptoms in patients
with RA.
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